According to filings with the U.S. Securities and Exchange Commission, Avant Genomics has raised $3,500,000.00 in new Angel/Seed funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the current round of funding include: TitletownTech, Halyard Ventures, Virginia Venture Partners, CAV Angels, Global Impact Fund.

About Avant Genomics
Avant Genomics is a biotechnology company focused on transforming cancer detection by automating critical liquid biopsy sample preparation steps in the laboratory. Its first-of-a-kind platform automates blood-based cancer detection workflows by using an enclosed fluidic cartridge and benchtop instruments that reduce dozens of manual steps to just loading the sample and removing the cartridge. The system integrates DNA enrichment and purification in a closed, 12-plex cartridge, delivering over 90% reduction in manual labor and more than 80% cost savings compared to conventional methods, while improving DNA recovery, consistency, and scalability from research labs to clinical testing environments. By removing workflow bottlenecks and simplifying complex sample preparation, Avant Genomics aims to make blood-based cancer detection faster, more accurate, and more accessible for laboratories everywhere. Through this automated approach to precision sample preparation, the company positions itself as an enabling technology provider for the broader adoption of liquid biopsy in cancer care.

To learn more, visit https://www.avant-genomics.com/
Linkedin: https://www.linkedin.com/company/avantgenomics/

Contact:
Rachelle Turiello, Chief Executive Officer
https://www.linkedin.com/in/rachelleturiello/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.